Why AI Agency Fundamentally Changes Risk
A Quality Manager’s Perspective of AI Agency Risk
Artificial intelligence (AI) is moving rapidly from passive assistance to active participation in regulated processes.
Many organisations are comfortable deploying AI as a static tool; for example, to help draft documents, search standard operating procedures (SOPs), or summarise information. In these cases, existing quality and validation approaches often feel sufficient.
However, a different risk profile emerges the moment an AI system is given agency i.e. the ability to decide what to do next and to act on those decisions. This is not simply a question of “stronger” or “smarter” technology. It is a structural shift that challenges the assumptions underpinning traditional quality systems.
For Quality Managers, this distinction matters because quality risk is not defined solely by technical accuracy. It is defined by who makes decisions, who executes actions, and who is responsible for outcomes. Agency alters all three, even when formal accountability remains unchanged.
This article explains, in quality‑system terms, why introducing agency fundamentally changes the risk profile of an AI system, and why it requires a different governance mindset from static tools or traditional automation.
Static tools create bounded, local risk
A static AI tool operates within clearly defined limits. Examples include an SOP chatbot, a document‑drafting assistant, or a data‑analysis helper that produces outputs on request. These systems do not act independently in the quality system.
From a process perspective, a static tool:
- Does not decide what happens next
- Does not execute actions in the system
- Does not change system state on its own
The quality implications are therefore relatively contained. Risk is localised to issues such as incorrect information, poor drafting, or misuse by the user. Importantly, the human remains the process owner at all times.
In quality terms, the system is an input, not a participant. Preventative and detective controls are familiar and well understood: output review, content validation, user training, disclaimers, and controlled use. Root cause analysis is usually straightforward because the failure point can be traced to either the input data or the user’s decision to rely on the output.
This bounded risk profile aligns well with existing Good Manufacturing Practice (GMP) thinking. The AI supports the process, but it does not influence outcomes unless a human chooses to act on its output.
AI agency introduces independent process participation
An AI system with agency behaves very differently. Rather than waiting for explicit, step‑by‑step instruction, an agent can:
- Select actions
- Execute actions
- Evaluate results
- Decide whether to continue, retry, or change course
At this point, the system is no longer merely supporting the process. It is participating in it.
This represents a structural risk shift, not a technical one. The system crosses from being a “tool used within a process” to an “actor within the process”. Even if the agent’s actions are limited to a defined domain, the quality system now includes a non‑human decision‑maker.
For Quality Managers, this is a critical distinction. Traditional quality frameworks assume that decisions are made by accountable humans and that automation simply executes predefined logic (i.e. deterministic outcomes). Agency breaks that assumption. Behaviour is no longer fully specified before execution, and outcomes may vary depending on context, timing, and feedback.
The risk profile therefore expands beyond output accuracy to include decision quality, action appropriateness, and behavioural consistency.
AI agency creates system‑level, emerging risk
With static tools, typical quality questions are task‑focused: Was the answer correct? Was the document drafted appropriately? With agency, the failure modes become broader and harder to enumerate.
Quality‑relevant questions now include:
- Was the right action taken at all?
- Was it taken at the right time?
- Did retries amplify error instead of correcting it?
- Did the system act outside its intended scope?
From a quality standpoint, risk becomes emergent. Errors can compound across steps, particularly when decisions are conditional rather than linear. A small misjudgement early in a sequence can cascade into a significant deviation later.
This also complicates root cause analysis. Decisions are distributed across multiple points, and behaviour depends on context and feedback loops rather than a fixed script. The traditional model of identifying a single failure point may no longer be sufficient.
In effect, agency turns task‑level risk into system‑level risk; a shift that demands different assurance mechanisms.
Regulating AI
Regulators are moving from general “computerised systems” expectations to AI‑specific control frameworks. In Europe, the EMA/PIC/S work programme includes a dedicated Annex 22 (Artificial Intelligence) alongside updates to Annex 11 and Chapter 4, signalling that AI will be assessed through lifecycle governance, data integrity, and supplier oversight, not one‑off qualification.
In the US, FDA/CDER has opened public consultation via its AI in Drug Manufacturing discussion paper and continues to use programs like the Emerging Technology Program to understand real‑world use cases and shape policy.
The challenge for agencies is that many AI systems are probabilistic, frequently updated by vendors, and can drift over time, making “validated state” harder to define. Inspectors therefore focus on what companies can control: intended use, training/production data governance, audit trails, performance monitoring, change control, and clear human authority for GMP‑critical decisions.
Practical guidance – what ‘good’ looks like for Quality Managers
Validate the control loop, not just the function
Static tools are validated by checking input/output accuracy, known edge cases, and representative test sets. Agents require validation of the decisionloop:
- how actions are selected,
- how outcomes are evaluated,
- how the system decides whether to proceed, retry, escalate, or stop.
Define explicit authority boundaries
Agents should have clearly documented authority limits.
- What decisions can the system make independently?
- What actions require mandatory human approval?
Ambiguity here is a major quality risk.
Design escalation and stop conditions
Validation must include scenarios where the correct behaviour is not to act. Quality systems should test whether the agent recognises uncertainty, escalating risk, or changing conditions and responds appropriately.
Build in human override mechanisms
Kill-switches, pause functions, and rollback mechanisms are not optional safeguards. They are core quality controls once agency is introduced.
Monitor behaviour, not just outputs
Output review alone is insufficient. Quality oversight must include behavioural monitoring: frequency of retries, deviation from expected pathways, boundary testing, and drift over time.
Treat agents more like safety‑critical systems
From a validation and governance perspective, AI agents resemble automated manufacturing cells or clinical decision support systems more than document templates or calculators. The assurance approach should reflect this higher level of system interaction and risk.
Common AI agency pitfalls to avoid
- Treating agents as “just better automation” and applying insufficient controls.
- Validating outputs without validating decision logic or stop conditions.
- Assuming accountability is unchanged because a human is “responsible on paper”.
- Over‑reliance on post‑hoc review instead of real‑time controls.
- Undefined or poorly documented authority limits.
- Inadequate escalation pathways when uncertainty increases.
- Excessive retries that amplify errors rather than correcting them.
- Lack of behavioural monitoring once the system is live.
- Insufficient change control when agents adapt or learn.
- Difficulty performing root cause analysis due to distributed decision‑making.
Each of these pitfalls weakens control effectiveness and increases the likelihood that issues will be detected too late.
Conclusion: an action‑oriented view
From a Quality Manager’s perspective, agency fundamentally alters the risk landscape. It expands the risk surface, weakens traditional preventative controls, and shifts the focus from output validation to behavioural governance.
This does not mean AI agents should not be used in regulated environments. It means they must be governed differently. Quality systems need to evolve to address decision‑making, authority, and timing, not just correctness.
Key actions to consider:
- Explicitly distinguish between tools and agents in your quality framework
- Update risk assessments to include emergent and system‑level risks
- Validate decision loops, not just functional accuracy
- Strengthen real‑time oversight and intervention mechanisms
- Ensure governance keeps pace with system capability
In short, agency turns AI from a quality risk within a process into a process risk itself.
PharmOut Services & Training
PharmOut supports organisations navigating emerging technologies within regulated environments, including AI‑enabled systems, automation, and digital quality frameworks. Our consultants work with Quality, Manufacturing, and Governance teams to align innovation with GMP expectations through risk assessment, validation strategy, and practical governance models. We also deliver targeted training to help teams understand how new technologies change quality assumptions and control effectiveness.
Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.
Frequently Asked Questions (FAQ)
A static tool provides outputs on request, while an agent can choose actions, execute them, and decide whether to continue based on feedback. That shift means the system participates in the process rather than just supporting it.
Because the primary risk moves from incorrect outputs to incorrect or poorly timed decisions and actions that can change system state. Failures can also cascade across multiple steps, making issues harder to detect and investigate.
Clear intended use and authority boundaries, evidence that the control loop was validated (including stop/escalation conditions), and robust data integrity, audit trails, monitoring, and change control. The emphasis is on what the company can demonstrate and control over the system’s lifecycle.
Validate the decision loop and guardrails, not just point-in-time outputs, test representative scenarios, boundary conditions, and failure modes (e.g., uncertainty, retries, out-of-scope prompts). Then use ongoing performance monitoring to confirm it remains within the validated envelope.
Treating agents like conventional automation, leaving authority limits ambiguous, and relying on post-hoc review instead of real-time controls and human override mechanisms. Weak change control (including vendor model updates) and lack of behavioural monitoring are also frequent gaps.
